- Home
- NEA vs SNY Comparison
NEA vs SNY Comparison
Compare NEA & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NEA | SNY |
|---|---|---|
| Founded | 2002 | 1994 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 119.4B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | NEA | SNY |
|---|---|---|
| Price | $11.51 | $47.50 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $61.50 |
| AVG Volume (30 Days) | 803.4K | ★ 2.6M |
| Earning Date | 01-01-0001 | 01-29-2026 |
| Dividend Yield | ★ 4.23% | 3.28% |
| EPS Growth | N/A | ★ 105.93 |
| EPS | N/A | ★ 8.67 |
| Revenue | N/A | ★ $53,890,648,839.00 |
| Revenue This Year | N/A | $2.48 |
| Revenue Next Year | N/A | $6.47 |
| P/E Ratio | ★ N/A | $5.61 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.20 | $44.62 |
| 52 Week High | $11.37 | $60.12 |
Technical Indicators
Market Signals| Indicator | NEA | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 49.06 | 36.30 |
| Support Level | $11.52 | $46.97 |
| Resistance Level | $11.65 | $49.24 |
| Average True Range (ATR) | 0.09 | 0.66 |
| MACD | -0.01 | -0.20 |
| Stochastic Oscillator | 33.46 | 14.16 |
Price Performance
Historical ComparisonAbout NEA Nuveen AMT-Free Quality Municipal Income Fund of Beneficial Interest Par Value $.01
Nuveen AMT-Free Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and the alternative minimum tax applicable to individuals, by investing in an actively managed portfolio of tax-exempt municipal securities. The company invest in Transportation, Utilities, Healthcare, Education and Civics, and other sectors, with maximum investment in Transportation.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.